Skip to content
Citation only via OpenAlex

Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients

Javier Donate‐Correa, Fernando Henríquez, Ernesto Martín‐Núñez, Nayra Pérez‐Delgado, Mercedes Muros‐de‐Fuentes, Carmen Mora Fernández, Juan F. Navarro‐González

Transplantation · 2016 · ▲ 20 citations

Abstract

BACKGROUND: Paricalcitol decreases intact parathyroid hormone and the frequency of secondary hyperparathyroidism after kidney transplantation. This proof-of-concept study aimed to assess the effect of paricalcitol on fibroblast growth factor-23/KLOTHO axis in renal transplants. METHODS: Twenty-nine subjects with secondary hyperparathyroidism received oral paricalcitol 1 μg/d for 3 months, and 8 patients matched by age, sex, and creatinine clearance, but with intact parathyroid hormone less than 100 pg/mL, were included as controls. RESULTS: Intact parathyroid hormone decreased in paricalcitol-treated patients (P < 0.0001). Serum fibroblast growth factor-23 enhanced (P < 0.01), whereas KLOTHO concentrations showed a trend to increase (P = 0.067). KLOTHO gene expression in peripheral blood mononuclear cells increased by 45.7% in paricalcitol-treated patients (P < 0.01), without change in controls. Paricalcitol administration resulted in a median percent decrease of 56% in methylated DNA levels of KLOTHO promoter (P < 0.001). The ratio of the unmethylated/methylated KLOTHO promoter DNA did not change in controls, but it increased by 177% in paricalcitol-treated subjects (P < 0.0001). The increase in this ratio was independently associated with the change in serum KLOTHO (r = 0.55, P < 0.01) and messenger RNA expression levels (r = 0.40, P < 0.05). CONCLUSIONS: Paricalcitol administration to renal transplant patients significantly reduced intact parathyroid hormone and increased fibroblast growth factor-23, with a trend to increase in serum KLOTHO. Paricalcitol-treated patients showed a decrease in the methylation of the KLOTHO promoter with an increment in the ratio of un-methyated/methylated DNA, which was associated with an increase of KLOTHO gene expression levels and serum KLOTHO concentrations. Long-term studies are needed to assess whether paricalcitol-induced increase in KLOTHO gene expression and serum concentrations may translate into beneficial clinical effects.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1097/tp.0000000000001339
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Donate‐Correa, J., Henríquez, F., Martín‐Núñez, E., Pérez‐Delgado, N., Muros‐de‐Fuentes, M., Fernández, C.M., &amp; Navarro‐González, J.F. (2016). Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. <em>Transplantation</em>. https://doi.org/10.1097/tp.0000000000001339
Vancouver
Donate‐Correa J, Henríquez F, Martín‐Núñez E, Pérez‐Delgado N, Muros‐de‐Fuentes M, Fernández CM, et al. Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. Transplantation. 2016. doi:10.1097/tp.0000000000001339.
BibTeX
@article{javier2016Effect, title = {Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients}, author = {Javier Donate‐Correa and Fernando Henríquez and Ernesto Martín‐Núñez and Nayra Pérez‐Delgado and Mercedes Muros‐de‐Fuentes and Carmen Mora Fernández and Juan F. Navarro‐González}, journal = {Transplantation}, year = {2016}, doi = {10.1097/tp.0000000000001339}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings